| Year |
Citation |
Score |
| 2012 |
Nimjee SM, Lohrmann JD, Wang H, Snyder DJ, Cummings TJ, Becker RC, Oney S, Sullenger BA. Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 391-7. PMID 22086230 DOI: 10.1038/mt.2011.226 |
0.8 |
|
| 2009 |
Nimjee SM, Oney S, Volovyk Z, Bompiani KM, Long SB, Hoffman M, Sullenger BA. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. Rna (New York, N.Y.). 15: 2105-11. PMID 19846574 DOI: 10.1261/rna.1240109 |
0.8 |
|
| 2009 |
Oney S, Lam RT, Bompiani KM, Blake CM, Quick G, Heidel JD, Liu JY, Mack BC, Davis ME, Leong KW, Sullenger BA. Development of universal antidotes to control aptamer activity. Nature Medicine. 15: 1224-8. PMID 19801990 DOI: 10.1038/nm.1990 |
0.8 |
|
| 2009 |
Becker RC, Oney S, Becker KC, Sullenger B. Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor. Annals of the New York Academy of Sciences. 1175: 61-70. PMID 19796078 DOI: 10.1111/j.1749-6632.2009.05017.x |
0.8 |
|
| 2008 |
Blake CM, Oney S, Nimjee SM, Sullenger BA. Aptamers and siRNAs in cardiovascular disease Rna Technologies in Cardiovascular Medicine and Research. 255-287. DOI: 10.1007/978-3-540-78709-9_13 |
0.8 |
|
| 2007 |
Becker RC, Oney S, Becker KCD, Rusconi CP, Sullenger B. Nucleic acid aptamers and their complimentary antidotes: Entering an era of antithrombotic pharmacobiologic therapy Hamostaseologie. 27: 378-382. PMID 18060250 |
0.8 |
|
| 2007 |
Oney S, Nimjee SM, Layzer J, Que-Gewirth N, Ginsburg D, Becker RC, Arepally G, Sullenger BA. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides. 17: 265-74. PMID 17854267 DOI: 10.1089/oli.2007.0089 |
0.8 |
|
| Show low-probability matches. |